Developing the evidence base for cancer chemoprevention: Use of meta-analysis

Current Drug Targets

Volumn 12, Issue 13, 2011, Pages 1989-1997

  Nikolopoulos, Georgios K ^a,b   Bagos, Pantelis G ^b   Bonovas, Stefanos ^a  

^a Hellenic Centre for Disease Control and Prevention   (Greece)

^b UNIVERSITY OF CENTRAL GREECE   (Greece)

Author keywords

Bias; Cancer chemoprevention; Heterogeneity; Meta analysis

Indexed keywords

CALCIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PRAVASTATIN; STREPTOKINASE;

ATTRIBUTABLE RISK; BIBLIOGRAPHIC DATABASE; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; CONFIDENCE INTERVAL; EMBASE; HAZARD RATIO; HEART INFARCTION; HUMAN; INFORMATION DISSEMINATION; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS (TOPIC); METHODOLOGY; NULL HYPOTHESIS; OVARY CANCER; PANCREAS CANCER; PREECLAMPSIA; PROSTATE CANCER; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; REVIEW; RISK FACTOR; SCISEARCH; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; STRATIFIED SAMPLE; STUDY DESIGN; SYSTEMATIC ERROR;

ANIMALS; ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; EVIDENCE-BASED MEDICINE; HUMANS; INFORMATION STORAGE AND RETRIEVAL; META-ANALYSIS AS TOPIC; NEOPLASMS; NUTRITIONAL SCIENCES; PUBLICATION BIAS; REGRESSION ANALYSIS; RISK ASSESSMENT;

EID: 82055161801     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011798184191     Document Type: Review

References (74)

1. Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA 1992; 268: 240-8.
2. McAlister FA, Clark HD, van Walraven C, et al. The medical review article revisited: has the science improved? Ann Intern Med 1999; 131: 947-51.
3. Mulrow CD. Rationale for systematic reviews. BMJ 1994; 309: 597-9.
4. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: W65-94.
5. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine, 2nd ed. New York: Oxford University Press, 2000.
6. Pearson K. Report on certain enteric fever inoculation statistics. Br Med J 1904; 3: 1243-46.
7. Beecher HK. The powerful placebo. J Am Med Assoc 1955; 159: 1602-6.
8. Glass GV. Primary, secondary and meta-analysis of research. Educ Res 1976; 5: 3-8.
9. Smith ML, Glass GV. Meta-analysis of psychotherapy outcome studies. Am Psychol 1977; 32: 752-60.
10. Feinstein AR. Meta-analysis: statistical alchemy for the 21st century. J Clin Epidemiol 1995; 48: 71-9.
11. Sutton AJ, Higgins JP. Recent developments in meta-analysis. Stat Med 2008; 27: 625-50.
12. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001; 323: 334-6.
13. Patsopoulos NA, Analatos AA, Ioannidis JP. Relative citation impact of various study designs in the health sciences. JAMA 2005; 293: 2362-6.
14. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-71.
15. Lam W, Sze PC, Sacks HS, Chalmers TC. Meta-analysis of randomised controlled trials of nicotine chewing-gum. Lancet 1987; 2: 27-30.
16. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 1988; 319: 1681-92.
17. McDonald S, Westby M, Clarke M, Lefebvre C; Cochrane Centres' Working Group on 50 Years of Randomized Trials. Number and size of randomized trials reported in general health care journals from 1948 to 1997. Int J Epidemiol 2002; 31: 125-7.
18. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354: 1896-900.
19. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344-9.
20. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987; 9: 1-30.
21. Stroup DF, Berlin JA, Morton S, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.
22. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-9, W64.
23. Normand SL. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 1999; 18: 321-59.
24. Berman NG, Parker RA. Meta-analysis: neither quick nor easy. BMC Med Res Methodol 2002; 2: 10.
25. Bonovas S, Tsantes A, Drosos T, Sitaras NM. Cancer chemoprevention: a summary of the current evidence. Anticancer Res 2008; 28: 1857-66.
26. Bonovas S, Filioussi K, Sitaras NM. Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies. Am J Gastroenterol 2008; 103: 2646-51.
27. Bonovas S, Filioussi K, Sitaras NM. Do nonsteroidal antiinflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. Br J Clin Pharmacol 2005; 60: 194-203.
28. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999; 91: 1459-67.
29. [United States of America National Library of Medicine. MEDLINE factsheet. Available at: http://www.nlm.nih.gov/pubs/factsheets/medline.html. Accessed July 26, 2010.
30. Scherer RW, Dickersin K, Langenberg P. Full publication of results initially presented in abstracts. A meta-analysis. JAMA 1994; 272: 158-62.
31. Dickersin K. How important is publication bias? A synthesis of available data. AIDS Educ Prev 1997; 9: 15-21.
32. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 1990; 263: 1385-9.
33. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991; 337: 867-72.
34. Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA 1992; 267: 374-8.
35. Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 1998; 279: 281-6.
36. Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997; 350: 326-9.
37. Egger M, Smith GD. Bias in location and selection of studies. BMJ 1998; 316: 61-6.
38. Ravnskov U. Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. BMJ 1992; 305: 15-9.
39. Ravnskov U. Frequency of citation and outcome of cholesterol lowering trials. BMJ 1992; 305: 717.
40. McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet 2000; 356: 1228-31.
41. Conn VS, Valentine JC, Cooper HM, Rantz MJ. Grey literature in meta-analyses. Nurs Res 2003; 52: 256-61.
42. Hopewell S, McDonald S, Clarke M, Egger M. Grey literature in meta-analyses of randomized trials of health care interventions. Cochrane Database Syst Rev 2007; MR000010.
43. Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol 1986; 4: 1529-41.
44. Hopewell S, Clarke M, Lefebvre C, Scherer R. Handsearching versus electronic searching to identify reports of randomized trials. Cochrane Database Syst Rev 2007; MR000001.
45. Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 2008; 123: 899-904.
46. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997; 315: 1533-7.
47. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
48. Thompson SG, Sharp SJ. Explaining heterogeneity in metaanalysis: a comparison of methods. Stat Med 1999; 18: 2693-708.
49. Bonovas S, Nikolopoulos G, Filioussi K, Peponi E, Bagos P, Sitaras NM. Can statin therapy reduce the risk of melanoma? A metaanalysis of randomized controlled trials. Eur J Epidemiol 2010; 25: 29-35.
50. Warn DE, Thompson SG, Spiegelhalter DJ. Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales. Stat Med 2002; 21: 1601-23.
51. [Bagos PG, Nikolopoulos GK. A method for meta-analysis of casecontrol genetic association studies using logistic regression. Stat Appl Genet Mol Biol 2007; 6: article 17.
52. [Bagos PG, Nikolopoulos GK. Mixed-effects poisson regression models for meta-analysis of follow-up studies with constant or varying durations. Int J Biostat 2009; 5: article 21.
53. Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 8: 101-29.
54. Hardy RJ, Thompson SG. Detecting and describing heterogeneity in meta-analysis. Stat Med 1998; 17: 841-56.
55. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
56. Bonovas S, Filioussi K, Sitaras NM. Paracetamol use and risk of ovarian cancer: a meta-analysis. Br J Clin Pharmacol 2006; 62: 113-21.
57. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million subjects. J Clin Oncol 2007; 25: 3462-8.
58. Bonovas S, Sitaras NM. Statins and cancer risk: a confounded association. Gastroenterology 2009; 137: 740.
59. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21: 1559-73.
60. Baker WL, White CM, Cappelleri JC, Kluger J, Coleman CI; Health Outcomes, Policy, and Economics (HOPE) Collaborative Group. Understanding heterogeneity in meta-analysis: the role of meta-regression. Int J Clin Pract 2009; 63: 1426-34.
61. Bonovas S, Sitaras NM. Does pravastatin promote cancer in elderly patients? A meta-analysis. CMAJ 2007; 176: 649-54.
62. Bonovas S, Nikolopoulos G, Sitaras NM. Efficacy and safety of more intensive lowering of LDL cholesterol. Lancet 2011; 377: 715.
63. Bonovas S, Nikolopoulos G, Sitaras NM. Commentary on pravastatin and cancer: need for individual patient data metaanalyses. Pharmacoepidemiol Drug Saf 2010; 19: 203-4.
64. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 2006; 24: 4808-17.
65. Egger M, Smith GD. Meta-Analysis. Potentials and promise. BMJ 1997; 315: 1371-4.
66. Lau J, Schmid CH, Chalmers TC. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J Clin Epidemiol 1995; 48: 45-57.
67. Lau J, Antman E, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction, N Engl J Med 1992; 327: 248-54.
68. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA 2005; 294: 218-28.
69. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized controlled trials. N Engl J Med 1997; 337: 536-42.
70. Ioannidis J, Lau J. Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses. Proc Natl Acad Sci USA 2001; 98: 831-6.
71. Bagos PG, Nikolopoulos GK. Generalized least squares for assessing trends in cumulative meta-analysis with applications in genetic epidemiology. J Clin Epidemiol 2009; 62: 1037-44.
72. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
73. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple graphical test. BMJ 1997; 315: 629-34.
74. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 2005; 23: 8606-12.